Table 1. Characteristics of patients with type 2 diabetes in three different groups divided according to pretreatment status (before administration of liraglutide).
| Drug naive (n = 9) | Previous OHAs (n = 64) | Switched from insulin (n = 82) | |
|---|---|---|---|
| Male:female (n) | 4:5 | 35:29 | 35:47 |
| Inpatients (%) | 7/9 (77.8%) | 32/64 (50.0%) | 18/82 (22.0%) |
| Age (years) | 57.4 ± 4.7 | 62.7 ± 1.4 | 63.1 ± 1.5 |
| DM duration (years) | 5.8 ± 3.3 | 12.8 ± 1.0* | 15.5 ± 1.1**,† |
| BMI (kg/m2) | 30.3 ± 2.4 | 29.4 ± 0.7 | 26.2 ± 0.6*,‡ |
| HbA1c (%) | 10.3 ± 0.9 | 9.0 ± 0.2 | 8.6 ± 0.2* |
| Gly‐A (%) | 28.7 ± 4.6 | 24.1 ± 0.7 | 24.3 ± 0.7 |
| Fasting CPR (ng/mL) | 2.4 ± 0.6 | 2.5 ± 0.2 | 1.7 ± 0.1‡ |
| Maximum CPR (ng/mL) | 4.6 ± 0.8 | 5.1 ± 0.3 | 3.5 ± 0.2‡ |
| Delta CPR (ng/mL) | 2.0 ± 0.7 | 2.5 ± 0.3 | 1.7 ± 0.1 |
| Urine CPR (μg/day) | 82.1 ± 19.3 | 97.1 ± 8.1 | 63.6 ± 5.3‡ |
All values are expressed as mean ± SEM (n = 155).
*P < 0.05, **P < 0.01 vs group of drug naïve; †P < 0.05, ‡P < 0.01 vs group of previous oral hypoglycemic agents (OHAs).
BMI, body mass index; CPR, C‐peptide immunoreactivity; DM, diabetes mellitus; Gly‐A, glycosylated albumin; HbA1c, glycated hemoglobin.